Aortic Stenosis: Determinants of Progression, Severity and Left Ventricular Remodeling

Condition(s) studied

Study summary

Aortic stenosis (AS) is the most frequent valvulopathy in Western countries. The prevalence of AS is constantly increasing due to the aging of the population. Although significant progress has been made in understanding the pathophysiological mechanisms underlying the onset and progression of AS, there is no medical treatment to slow or prevent its progression. The only treatment available is Aortic Valve Replacement (AVR) performed by surgery or by catheterization (TAVI).

AS is associated with an increase of post-load which leads the left ventricular myocardium to hypertrophy. Associated with hypertrophy, myocardial fibrosis will gradually develop. Despite interesting data, many unknowns persist and remain to be identified.

The aim of the study is to evaluate prospectively the progression and impact of AS in 500 patients using clinical, biological, echocardiographic and MRI parameters performed annually.

Eligibility

Primary outcome measure(s)

• Composite primary endpoint: haemodynamic and anatomical progression of Aortic Stenosis — Year 1
  CT scan and MRI
• Composite primary endpoint: haemodynamic and anatomical progression of Aortic Stenosis — Year 2
  CT scan and MRI
• Composite primary endpoint: haemodynamic and anatomical progression of Aortic Stenosis — Year 3
  CT scan and MRI
• Composite primary endpoint: haemodynamic and anatomical progression of Aortic Stenosis — Year 4
  CT scan and MRI

Trial sites (1)

More University Hospital, Rouen trials in France

Other trials for the same condition